US Drug Test Centers Blog
Specimen Validity Testing: Why Collection Procedure Is Your Real Safeguard
Employers ask a version of this question constantly: how would we know if someone tampered with a drug test?
It’s the wrong question, and asking it sends people down an unproductive path. Researching what is being sold, trying to stay ahead of it, and treating the whole thing as a contest. It is not a contest. The laboratory and the collection process are designed to detect tampering as a category, without anyone needing to know what specific method was attempted.
The better question is whether your program's procedures are actually being followed. That is where employers have control, and it is where programs typically fail.
What Specimen Validity Testing Is
Every specimen processed under federal testing rules undergoes specimen validity testing before or alongside the drug screen itself. It is not an add-on and not something an employer requests separately.
Validity testing asks a simple question: is this a genuine, unaltered human urine specimen? The laboratory evaluates several characteristics: creatinine concentration and specific gravity, which together indicate whether the specimen is physiologically normal or excessively watered down, pH, which falls outside human range if certain substances have been introduced, and the presence of oxidizing adulterants and other compounds that do not occur in human urine.
The important point for employers is that the lab is not looking for a specific product. It is checking whether the specimen behaves like urine. That approach does not go stale as new products appear.
The Four Results You Need Your Policy to Address
Validity testing produces four outcomes beyond a straightforward negative or positive. Your policy should say what happens in each case, in writing, before you encounter one.
- Dilute. The specimen is genuine but excessively diluted. Under DOT rules a negative dilute generally results in a recollection, sometimes under direct observation depending on the values involved. Critically, a negative dilute is a negative result, not a violation, and should not be treated as one. A positive dilute is a positive.
- Substituted. The specimen's characteristics are not consistent with human urine at all. This is handled as a refusal to test.
- Adulterated. A substance has been introduced that is not found in normal urine, or a characteristic falls outside physiologically possible range. Also handled as a refusal.
- Invalid. The laboratory cannot obtain a valid result due to either interference, inconsistent readings, or an unidentifiable substance. The Medical Review Officer contacts the employee to determine whether a legitimate medical explanation exists. If there is none, a recollection under direct observation is typically required.
Employers who have not defined these in advance tend to improvise, and improvised responses applied inconsistently across employees are what generate legal exposure.
Refusal to Test Is Your Most Underused Tool
This is the single most valuable thing for an employer to understand, and it resolves most of the anxiety behind the original question.
Under DOT rules, a refusal to test carries the same consequences as a verified positive. And refusal covers considerably more than saying no. It includes failing to appear for a scheduled test within a reasonable time, leaving the collection site before the process is complete, failing to provide a sufficient specimen without a valid medical explanation, failing to permit an observed collection when one is required, admitting to the MRO that a specimen was adulterated or substituted, and possessing or wearing a device intended to interfere with the collection.
The practical implication: an employer does not have to prove what was in a specimen. Substituted and adulterated results are refusals. Conduct at the collection site that obstructs the process is a refusal. The framework is built so the employer does not need to win a forensic argument.
Collection Procedure Is the Actual Control
Laboratory validity testing is the backstop. The collection site is the front line, and this is where employer programs most often have gaps; not because the rules are unclear, but because nobody has verified that a particular site is following them.
A properly run collection includes securing the water supply and adding bluing agent to the toilet, restricting personal belongings from the collection area, reading the specimen temperature within four minutes of the void, keeping the employee at the site until the process is complete, maintaining an unbroken chain of custody on the federal form, and collecting a split specimen so the employee retains the right to request testing of the second portion.
Any employer can verify this. Visit your collection site. Ask to see the procedure. Ask how they handle a shy bladder situation, an out-of-range temperature, and a situation where a same-sex observer is not available. A site that cannot answer those questions clearly is a liability, and you will discover it during an audit or a wrongful termination claim rather than on a Tuesday afternoon.
When Direct Observation Is Required and What Just Changed
Direct observation is not discretionary and is not something a collector chooses to impose. Under Part 40 it is required in defined circumstances: for all return-to-duty and follow-up tests, when the specimen temperature is out of range or the specimen shows signs of tampering, when the collector observes conduct or materials suggesting an attempt to interfere, and when the MRO directs it following certain results.
There is also a recent change worth checking your policy against. On May 11, 2026, DOT published a final rule amending Part 40, effective June 10, 2026. It addresses what happens when a directly observed collection is required and a same-sex observer is not available at the site. Because oral fluid testing is not yet operationally available, the rule provides that the collector contacts the Designated Employer Representative, who either arranges a same-sex observer or directs the employee to another site for a directly observed urine collection. The rule also updated terminology throughout Part 40.
Two things follow for DOT-regulated employers. Your written policy and your standing orders with your collection sites should reflect the current language and procedure; auditors reviewing policies after the effective date will flag outdated wording as a compliance gap. And your DER needs to know they may receive that call and what to do when it comes.
Specimen Type Changes the Equation
Not every specimen type presents the same vulnerabilities, which is worth considering when you design a program.
Oral fluid collection is inherently observed. The collector watches the specimen being provided, which removes an entire category of concern. Hair testing is difficult to interfere with and covers a much longer window, though it is not authorized for federally mandated testing. Urine remains the federal standard and has the most developed validity testing framework behind it precisely because it is the specimen collected out of direct view.
For non-DOT programs, employers have latitude to choose. That choice should be deliberate rather than inherited.
What Non-DOT Employers Should Borrow
Nothing requires a non-regulated employer to follow Part 40. Borrowing its structure is still the most efficient way to build a defensible program:
- Use collection sites and laboratories that follow federal collection procedures as a matter of practice
- Require specimen validity testing rather than assuming it is included
- Use an MRO to review results before any employment action
- Define refusal to test in your policy, including conduct at the collection site
- Write your dilute, adulterated, substituted, and invalid procedures before you need them
- Apply every one of these consistently to every employee in the same category
Consistency is the point. A well-designed program that is applied unevenly is harder to defend than a simple one applied the same way every time.
US Drug Test Centers provides DOT and non-DOT testing through SAMHSA-certified laboratories with MRO review, across a nationwide network of collection sites following federal collection procedures. We also build drug-free workplace policies and provide DER and supervisor training. If you are not certain your current collection sites are following proper procedure, that is worth confirming before it matters.
This article is provided for general informational purposes and is not legal advice. DOT-regulated employers should verify current requirements against 49 CFR Part 40 and applicable operating administration rules.
